Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Orders 12 Firms To Collect Data On Dynamic Spine Stabilization Devices

This article was originally published in The Gray Sheet

Executive Summary

FDA is ordering 12 spine device manufacturers to begin collecting post-market data on how well their devices fare in doing what they are 510(k)-cleared to do: support spinal fusion procedures

You may also be interested in...



Semi-Rigid Spine Systems Will Escape PMAs, But Not Clinical Mandate

US FDA has completed a long-running effort to reclassify pedicle screw systems, which are widely used devices for spine fusion procedures. The final policy: all pedicle screws intended as an adjunct to fusion surgery are class II/special controls devices, but "semi-rigid" systems will require clinical data to support 510(k) clearance while more traditional, rigid systems will not.

PMAs Proposed For Dynamic Spine Stabilization Devices

The agency proposes to maintain 510(k) standards for rigid pedicle screw systems but wants dynamic spine stabilization devices, designed to provide more motion and flexibility, to go the PMA route.

FDA Emphasizes Efficiency In 522 Surveillance Order Draft Guidance

FDA is emphasizing the need for “early and ongoing” interaction between regulators and device companies targeted by the agency in Section 522 post-market surveillance orders in a draft guidance issued Aug. 16.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel